Novel Technologies and Theoretical Models in Radiation Therapy of Cancer Patients Using 6.3 MeV Fast Neutrons Produced by U-120 Cyclotron

L. I. Musabaeva$^{1,a}$, Zh. A. Startseva$^{1,2,b}$, O. V. Gribova$^{1,2,c}$, V. V. Velikaya$^{1,2,d}$, and V. A. Lisin$^{1,e}$

$^1$ Tomsk Cancer Research Institute, Kooperativny Street 5, Tomsk, 634050 Russia
$^2$ National Research Tomsk Polytechnic University, Lenin Avenue 30, Tomsk, 634050 Russia

$a)$ Corresponding author: musabaevaLI@oncology.tomsk.ru
$b)$ zhanna.alex@rambler.ru
c) gribova79@mail.ru
$d)$ viktoria.v.v@inbox.ru
e) Lisin@oncology.tomsk.ru

Abstract. The analysis of clinical use of neutron therapy with 6 MeV fast neutrons compared to conventional radiation therapy was carried out. The experience of using neutron and mixed neutron and photon therapy in patients with different radio-resistant malignant tumors shows the necessity of further studies and development of the novel approaches to densely-ionizing radiation. The results of dosimetry and radiobiological studies have been the basis for planning clinical programs for neutron therapy. Clinical trials over the past 30 years have shown that neutron therapy successfully destroys radio-resistant cancers, including salivary gland tumors, adenoid cystic carcinoma, inoperable sarcomas, locally advanced head and neck tumors, and locally advanced prostate cancer. Radiation therapy with 6.3 MeV fast neutrons used alone and in combination with photon therapy resulted in improved long-term treatment outcomes in patients with radio-resistant malignant tumors.

INTRODUCTION

Neutron therapy is used alone or in combination with photon therapy. The dependence of the frequency of regression of primary, recurrent and metastatic head and neck tumors and morphological characteristics of the tumor as well as contribution of fast neutrons to the total dose has been established. In neutron and neutron-photon therapy, the character and the rate of reoxygenation of superficial tumors was found to depend on the size of the primary tumor. In this context, the radiation therapy regimens based on the use of mixed gamma-neutron irradiation allow the group of cancer patients to be significantly expanded. Studies on the activity of the saliva enzymes including alpha-amelase, kallikrein and kallikreinogen were carried out for the first time in patients with oral cavity cancer, who underwent neutron and neutron-photon therapy. Suppression of enzymatic activity of saliva was more clearly pronounced in patients subjected to neutron therapy than in patients subjected to the conventional gamma-therapy. Indices of saliva enzymatic activity in the process of combined radiotherapy were used as a criterion of tolerance of salivary glands in the patients with head and neck cancer. Copper steam laser irradiation, magnetic therapy and ozone therapy have been shown to be useful for the treatment and prevention of radiation-induced skin damage in the long-term follow-up of patients with breast cancer local recurrence. Thus, due to the novel radiotherapy technologies, 6.3 MeV fast neutrons produced by U-120 cyclotron have been used for the treatment of cancer patients at the Tomsk Cancer Research Institute for more than 30 years.
DOSIMETRIC AND RADIOBIOLOGICAL CHARACTERISTICS OF NEUTRON AND NEUTRON-PHOTON THERAPY

All regimens of neutron and mixed neutron-photon therapy are based on radiobiological and mathematical models. The time, dose and fractionation (TDF) model was applied first, then the linear quadratic model (LQM) was used to measure spatial neutron dose distribution and RBE of fast neutrons. The radiobiological properties of a cyclotron-produced fast neutron beam relative to gamma rays allow us to consider neutron therapy as one of the ways to improve radiation therapy results.

A computer program for measuring spatial dose distribution in neutron and mixed gamma-neutron therapies has been created, allowing the total distribution of the absorbed and isoeffective doses for the mixed gamma-neutron therapy to be calculated [1]. The main advantage of new regimens is an 8-fold increase in the frequency of breast cancer local recurrence and increase in the 5-year disease-free survival rate of patients with various types of cancer. The use of the TDF and LQ models contributes to the prediction of radiation-induced damage to normal tissues.

NEUTRON THERAPY REGIMENS

The following two neutron therapy regimens were used: (1) 2 fractions per week, 1.2–1.4 Gy single dose (3.2–3.1 RBE), 5.3–4.5 Gy photon-equivalent dose, 40–60 Gy total dose, for 4–6 weeks; (2) 3 fractions with a 48–72 hour interval, 1.8–2.4 Gy single dose (2.6–2.8 RBE), 6.7–6.8 Gy photon-equivalent dose, 38–40 Gy total dose, for 8–12 days. It should be noted that the applied regimens of fast neutron dose fractionation, particularly in the regime 2, when only three 1.8–2.4 Gy fast neutrons fractions were used, represent enlarged single dose version.

These regimens were used for preoperative and postoperative neutron therapy alone and in combination with external beam radiotherapy for both curative and palliative cancer treatment. Results of clinical trials demonstrated that neutron therapy was well tolerated, and there was no evidence of severe radiation induced reactions.

RESULTS AND DISCUSSION

The method of neutron-photon therapy for locally advanced breast cancer was developed (RF patent No. 2186591) [2]. To assess the efficacy of preoperative neutron therapy, the treatment regimen 2 (3 fractions, 2.6–2.8 RBE, 6.7–6.8 Gy photon-equivalent dose) was used. Normal and tumor tissue pathological response was assessed after radical mastectomy. The histological study showed that fibrous tissue of different maturity predominated both in the centre and on the periphery of the tumor [3]. Tumor cells persisted in groups and individually, but almost in 100% of the cases they were degenerately changed. The number of normal mitoses in tumors was minimal (20.88 ± 2.0%), while the number of pathologic mitoses was maximum (79.12 ± 2.8%). The greatest number of “lethal mitoses” was observed in tumors after neutron therapy and the minimum number after the conventional photon therapy, thereby indicating that 6.3 MeV fast neutron therapy resulted in a significant damage to tumor cells compared to the standard photon therapy. The replacement of the tumor with fibrous tissue of various degrees of maturity was typical of preoperative neutron therapy for breast cancer. The neutron therapy regimen consisting of 3 fractions resulted in a long-term disease-free follow-up period in patients with locally advanced cancer. Late radiation-induced damage to normal tissues was corresponded to grade 1 toxicity (according to the Radiation Therapy Oncology Group/The European Organization for Research, and Treatment of Cancer (RTOG/EORTC).

Forty-one patients with head and neck cancer and 44 patients with musculoskeletal cancer underwent preoperative neutron and mixed neutron-photon therapies followed by surgery. No complications in the postoperative period were observed in cases when the total dose of neutron radiation therapy was ≤40 Gy. The increase in the absorbed neutron dose or the prolonged follow-up period led to the growth in the frequency of postoperative complications. Histological examination of surgical specimen showed that the microscopic features of radiation-induced damage to tumor tissue were similar both after neutron and mixed neutron-photon radiation therapies. Radiation-induced damages were manifested as degenerative changes, necrobiosis and necrosis of parenchymal cells. Neutron therapy contributed to the reduction in the tumor mitotic index, number of normal mitoses and number of cells emerging from mitoses. There was a growing level of pathological mitoses, including scattering, chromosome fragmentation, asymmetry and K-mitoses. The DNA accumulation index was 2.48 after preoperative neutron therapy and 4.6 after photon therapy. Response of osteogenic sarcoma to neutron and mixed neutron-photon therapy differed by more marked changes in comparison with that to the conventional photon therapy.
Preoperative neutron therapy was given to 46 patients with cancer of the maxillary sinus and nasal cavity. The control group comprised 45 patients who received the conventional photon therapy. The overall 5-year survival rates were: 62 ± 9.6% in the neutron therapy group and 42 ± 9.5% in the control group. The 5-year recurrence-free survival rates were 68 ± 8.2% and 40 ± 9.2%, respectively. At a follow-up of 10 years, 11 of the 38 patients (29%) are still alive in the neutron therapy group and none of the patients (0%) is alive in the control group.

Results of postoperative neutron therapy for patients with parotid gland cancer \((n = 52)\) were as follows: the 5-year relapse-free survival rate was 72.4 ± 9.8% and the 10-year survival rate was 32.2 ± 16.8%. In the control group the 5-year survival rate was 25.6 ± 19.1% \((p < 0.05)\). In patients with salivary gland cancer \((n = 22)\), the 3- and 5-year survival rates were 60.6 ± 13.6% and 48.5 ± 15.3%, respectively after neutron therapy compared to 30 ± 16.9% and 0% after photon therapy \((p < 0.05)\). In patients with thyroid cancer \((n = 33)\), the overall 5-year- and relapse-free survival rates were 70.4 ± 7% and 72.4 ± 9.8%, respectively after postoperative neutron therapy compared to 40% after combined neutron and photon therapy.

The method of radiation therapy with fast neutrons and neutron + photon therapy for 95 patients with breast cancer local recurrence was developed [4]. The overall 6-year survival rate was 92.2 ± 5.7% versus 51.5 ± 9.1% in the control group. Late radiation-induced skin damages were observed in 23% of cases with local recurrences. The incidence and character of acute and late radiation-induced skin reactions in breast cancer patients after treatment with preoperative neutron and photon therapy are shown in Fig. 1 and Table 1.

In patients with salivary gland cancer, who received combination treatment with postoperative neutron therapy, the 3-, 5- and 10-year survival rates were 70.4 ± 7.8%, 64.5 ± 9.1% and 32.2 ± 16.8%, respectively. In the control group patients, the 3-year overall survival rate was 51.1 ± 12.8% and the 5-year survival rate was 25.6 ± 19.1%.

The 3- and 5-year overall survival rates in patients with inoperable salivary gland cancer, who received fast neutron therapy alone, were 60.6 ± 13.6% and 48.5 ± 15.3%, respectively. In the control group, the corresponding values were 30 ± 16.9% and 0%, respectively [5]. The 3- and 5-year recurrence-free survival rates were 80.4 ± 6.8% and 72.4 ± 9.8% for salivary gland cancer patients treated with surgery and postoperative neutron therapy, respectively. In the control group, the 3- and 5-year recurrence-free survival rate was 42.4 ± 18.6%.

**Incidence of acute and late radiation-induced skin reactions in breast cancer patients after treatment with preoperative neutron and photon therapy** (scale RTOG/EORTS, 1995)

![Incidence of acute and late radiation-induced skin reactions in breast cancer patients after treatment with preoperative neutron and photon therapy](image)

**Post-radiation reaction [1]** – Slight atrophy, change in skin pigmentation, mild epilation, slight induration (fibrosis) and decrease in the amount of subcutaneous fat

**Post-radiation reaction [2]** – Island atrophy, moderate telangiectasis, moderate symptomatic-free fibrosis in the radiation area

**Post-radiation reaction [3]** – Severe atrophy, massive telangiectasis, noticeable induration and decrease in the amount of subcutaneous fat

**FIGURE 1.** Incidence and character of acute and late radiation-induced skin reactions in breast cancer patients after treatment with preoperative neutron and photon therapy (scale RTOG/EORTS, 1995)
### TABLE 1. Short-term treatment results of radiation therapy for patients with breast cancer local recurrences with respect to the type of ionizing radiation

<table>
<thead>
<tr>
<th>Treatment response</th>
<th>Neutron therapy, total radiation dose is 40–60 isoGy ($n = 7$)</th>
<th>Neutron-photon therapy, total radiation dose is 60–65 isoGy ($n = 40$)</th>
<th>Electron therapy, total radiation dose is 60–65 isoGy ($n = 41$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete response</td>
<td>7 (100%)</td>
<td>37 (93%)</td>
<td>25 (61%)</td>
</tr>
<tr>
<td>Partial response</td>
<td>–</td>
<td>3 (7%)</td>
<td>5 (12%)</td>
</tr>
<tr>
<td>Stable disease</td>
<td>–</td>
<td>–</td>
<td>11 (27%)</td>
</tr>
<tr>
<td>Disease progression</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Immediate response rate of inoperable salivary gland cancer was higher to fast neutrons than to conventional photon therapy. In neutron therapy group, complete tumor regression was observed in 23 cases (58%), partial regression in 15 cases (37%). No response to therapy with evidence of disease progression was noted in two cases (5%). In the control group, partial tumor regression was observed in 5 cases (62.5%). No response to radiotherapy was recorded in 2 cases (25%), complete regression occurred in one case (12.5%).

The analysis of long-term treatment outcomes of patients with thyroid cancer showed the overall five-year survival rate of 32.8 ± 15.1% in patients with anaplastic thyroid carcinoma and 63.4 ± 7.8% in patients with medullary carcinoma [6]. All patients with squamous cell carcinoma of the thyroid gland died of distant metastases without evidence of local recurrence within 1-year follow-up.

Radiation-induced skin damages (mainly grade I erythema according to RTOG scale) were observed in 81% of patients with salivary gland cancer who received combination treatment including surgery and postoperative neutron or neutron-photon therapy [7]. In patients with salivary gland cancer, who received neutron or neutron-photon therapy alone, radiation-induced skin damages were noted in 96% of cases.

In patients with thyroid cancer, who were treated with fast neutrons in the postoperative period, radiation-induced skin reactions were observed in 73% of cases and were mainly represented by erythema (52%). In patients with thyroid cancer, who received neutron-photon therapy alone, dry and moist desquamation was observed in 81% of cases.

**CONCLUSION**

The rates of recurrence-free and overall survival for patients with radio-resistant cancer treated with combined modality treatment including fast neutron therapy were significantly higher than those observed in patients treated with conventional photon therapy. The assessment of 6.3 MeV fast neutron therapy regimens in terms of tumor response and overall disease-free survival indicate the advantage of fast neutron therapy over the conventional photon therapy in patients with radio-resistant malignant tumors. Clinical trials of neutron-photon therapy used alone and in combination with surgery for cancer patients have shown feasibility of increasing the effectiveness of treatment due to reduction in the incidence of local recurrences. In addition, satisfactory treatment tolerance and absence of severe specific complications dictate the necessity of prospective studies to improve treatment outcomes. The accumulated experience in the use of neutron and neutron-photon therapies for patients with radio-resistant cancer has shown that further development of this modality is necessary to achieve the best outcomes for our patients.

**ACKNOWLEDGMENTS**

The study was financially supported by the Fundamental Research Program of the Russian Academy of Sciences, project No. 093.
The study reported in this article was conducted according to accepted ethical guidelines involving research in humans and/or animals and was approved by an appropriate institution or national research organization. The study is compliant with the ethical standards as currently outlined in the Declaration of Helsinki. All individual participants discussed in this study, or for whom any identifying information or image has been presented, have freely given their informed written consent for such information and/or image to be included in the published article.

REFERENCES

1. V. A. Lisin, Dosimetry computer therapy planning of malignant neoplasms by fast neutron beam of U-120 cyclotron, Medical Radiology 1, 26–28.